Define the source, EPA/DHA basis and oxidation plan before calling a gummy “omega-3.”
Sucotond USA coordinates non-confidential feasibility review for U.S. brands planning custom omega-3 gummies. The review connects source material, fatty-acid identity, oil or powder form, serving and label basis, gummy process, oxidation/sensory methods, package and time-point evidence before a commercial commitment.
This is a custom-project service page, not a claim that one stocked source, EPA/DHA level, oil, powder, emulsion, method, formula or shelf life fits every project.
Project Starting Point“Omega-3 oil” is not a complete product specification
A reviewable brief distinguishes the biological source and supplier material, the individual fatty acids and label quantities, the delivery format entering the gummy and the quality evidence attached to the final product.
Source identity
Fish, krill, microalgal and other sources are not interchangeable descriptions. Capture source organism/material, supplier, lot, processing context and applicable allergen review.
Fatty-acid identity
ALA, EPA and DHA are different omega-3 fatty acids. State the intended dietary ingredient, individual amounts, combined basis and serving instead of using “omega-3” alone.
Oil, powder or emulsion
Bulk oil, encapsulated powder and emulsion systems can differ in fatty-acid concentration, carrier, antioxidant, chemical form, moisture interaction and process behavior.
Oxidation and sensory evidence
Primary/secondary oxidation measures, calculated indices, volatile/sensory observations and shelf-life results answer different questions and can be matrix-sensitive.
Eight decisions that make an omega-3 gummy project reviewable
1. Source and supplier material
- Fish, algal, krill or other reviewed source
- Source species/organism and supplier identifier where applicable
- Lot, production form and identity/composition records
- Source-specific allergen and safety review owner
2. Fatty-acid and label target
- ALA, EPA, DHA and combined wording kept distinct
- EPA plus DHA—not only total oil
- Amount per serving and acceptable piece count
- Supplement Facts, source and claim approval responsibility
3. Material format and carrier
- Oil, powder, beadlet, emulsion or other reviewed form
- Fatty-acid concentration and chemical-form context
- Carrier, wall material, antioxidant and other excipients
- Storage, handling and supplier change controls
4. Gummy feasibility and sensory system
- Target load, piece weight and serving count
- Gelling, sweetener, acid, flavor, color and coating system
- Mixing, addition, temperature and hold-time questions
- Odor, taste, appearance and sample-to-scale acceptance
5. Fatty-acid and oxidation methods
- EPA/DHA composition method and reporting basis
- Primary, secondary or calculated oxidation question
- Sample preparation and flavored-gummy matrix suitability
- Laboratory, specification source, units and limitations
6. Contaminant and allergen scope
- Source- and market-specific risk assessment
- Applicable contaminant criteria and method ownership
- Major-allergen declaration and cross-contact review
- Supplier records versus finished-product verification
7. Package and stability plan
- Container, closure, count, headspace and protective assumptions
- Light, oxygen, moisture, temperature and distribution questions
- Formula/package/batch/time-point coverage
- Trend, excursion and shelf-life decision owners
8. Commercial and document scope
- Target market, volume stage and delivery point
- Component, batch, laboratory, package and stability records
- Disclosure and publication rights
- MOQ, timing and quote validity confirmed after review
Put each number in the right column
Omega-3 supplement formulations vary, so NIH advises checking the types and amounts actually present. A headline oil quantity does not by itself identify the amount of each constituent. NIH omega-3 fact sheet
These fictional quote cards illustrate reporting arithmetic only. They are not actual supplier specifications, recommended intakes, proof of finished-gummy content or available Sucotond formulations. All figures in Card A are assumed to share a compatible reporting basis; without that assumption, its subtraction is not justified.
| Field | Fictional quote A | Fictional quote B |
|---|---|---|
| Serving | Two pieces | Two pieces |
| Oil-material mass per serving | 600 mg | 800 mg |
| Total omega-3 per serving | 180 mg | Not stated |
| EPA | 60 mg per serving | 30 mg per piece |
| DHA | 90 mg per serving | 45 mg per piece |
| EPA + DHA per serving, calculated | 60 + 90 = 150 mg | (30 + 45) × 2 = 150 mg |
What the comparison supports
The quoted EPA-plus-DHA totals are arithmetically equal after normalizing the serving basis. B has a larger oil-material number, but that does not show a larger quoted EPA-plus-DHA amount. Neither equality proves equivalent source composition, chemical form, analytical method, oxidation condition, formulation performance or price value.
In A, 180 − 60 − 90 = 30 mg is the implied amount of other omega-3 constituents under the explicit compatible-basis assumption. The arithmetic does not identify those constituents or verify the supplier's figure. Ask for the composition specification if that distinction matters to the brief.
In B, total omega-3 remains unknown. Do not relabel the known 150 mg EPA-plus-DHA sum as total omega-3; other constituents may be present but are not quantified on this card. Do not call the remaining oil mass “filler” either. Its composition has not been supplied.
A powder or percentage creates another basis question
If a later quote changes from an oil to an encapsulated powder, establish whether each percentage applies to the whole powder, its oil fraction, total fatty acids or another stated basis. A percentage without its denominator cannot fill the table reliably. Likewise, do not directly subtract constituent masses expressed using incompatible chemical or analytical conventions.
Use this compact reconciliation record:
Quote revision | supplied-material form | mass denominator | serving definition | EPA amount/basis | DHA amount/basis | total omega-3 amount/basis | calculated fields | supporting specification | unresolved difference
Mark the source of every populated field. A calculation from an ingredient specification is not a measured result from the finished product; a composition result is not automatically evidence of stability in the proposed package.
Use the formula-space resource for material-mass accounting and the COA guide for report scope. Bring unresolved fields into the RFQ template before treating the offers as comparable.
Make every omega-3 field carry its own evidence question
The table is intentionally not prefilled with a source, EPA/DHA amount, oxidation limit or shelf life. Those values become publishable only when they belong to the approved project and evidence scope.
| Project field | Buyer input | Required confirmation before commitment |
|---|---|---|
| Source identity | Fish/algal/other direction and source constraints | Supplier, source organism/material, lot, processing form and identity/composition specification |
| Fatty-acid basis | ALA, EPA, DHA, combined amount and serving target | Individual/combined assay basis, units, serving, label and acceptance criteria |
| Material format | Oil, powder, emulsion or acceptable alternatives | Concentration, chemical-form context, carrier, antioxidant, storage and handling |
| Gummy system | Load, piece count, gelling/sweetener system and sensory direction | Approved formula, process feasibility, sample transfer, controls and change triggers |
| Quality methods | Fatty-acid, oxidation and contaminant evidence expected | Analyte, method, preparation, matrix suitability, units, time point and limitations |
| Label and allergen | Proposed source/amount/claim wording and market | Supplement Facts, ingredients, applicable allergen declaration, claims and artwork revision |
| Package and shelf life | Container, closure, count, storage wording and proposed date | Commercial formula/package, conditions, batches, time points, results, trend and decision |
| Commercial terms | Volume stage, delivery point and launch window | Materials, package, evidence scope, quantity, timing and current quote |
Connect the received source material to the labeled commercial lot
Supplier material
Source, lot, form, composition, carrier and component criteria.
Incoming decision
Identity/composition evidence, sampling and supplier qualification.
Approved formula
Serving, gummy system, label basis, package and controlled revision.
Commercial process
Handling, mixing, controls, master/batch records and deviations.
Finished evidence
Fatty acids, oxidation, contaminants and quality disposition.
Time and label
Package, storage, time points, effective artwork and distributed lot.
Use the product specification checklist to define acceptance fields, the laboratory report checklist to review method and result scope, the shelf-life evidence checklist to connect package and time points, and the label/artwork checklist to control source, amount and allergen wording.
NIH distinguishes ALA, EPA and DHA—and multiple supplement forms
NIH's Office of Dietary Supplements describes ALA, EPA and DHA as different omega-3 fatty acids and notes that supplements can use sources such as fish oil, krill oil, cod liver oil and algal oil. It also describes multiple chemical forms. That supports a buyer requirement to identify the source, material form and EPA plus DHA—not only total oil. It does not establish a Sucotond formulation, absorption result or health outcome.
Source, serving, dietary ingredient and other ingredients must reconcile
Label the actual project basis
FDA's dietary-supplement materials describe serving and dietary-ingredient declarations as well as source and other-ingredient labeling. For an oil powder or emulsion, the project file should reconcile the EPA/DHA basis with the source oil, carrier, wall material, antioxidant, flavor and other formula inputs.
Review allergens by source and formula
FDA identifies fish and Crustacean shellfish among major food allergens and provides guidance that includes dietary-supplement situations. The responsible firm should review the exact source ingredient, processing, other ingredients and label configuration rather than applying an unqualified allergen statement to every omega-3 project.
These market surveys do not validate a finished omega-3 gummy
Read the sample and method limits before transferring a published oxidation result to a gummy project:
- Jackowski et al. (2015) studied products purchased in Canada in 2014. Gummies were explicitly excluded because the study's methods could not determine their composition and oxidation status. Some other products also could not be measured, so the collected sample is not the denominator for every reported metric.
- Hands et al. (2024) reported 72 U.S. products sampled in 2014–2020. The abstract lists enteric, liquid, softgel and spray delivery systems, not gummies. It reports TOTOX above the voluntary criterion it used in 23 of 34 flavored products (68%) and 5 of 38 unflavored products (13%). These are study-specific results, not gummy failure rates or proof that flavoring caused oxidation.
- Pasini et al. (2022) examined 20 unflavored French-market supplements and reported compliance with the voluntary oxidation criteria applied. A different sample is not a direct contradiction, and this study does not provide validation of a finished gummy.
Higher readings need interpretation: the Canadian authors also describe flavor interference in p-anisidine testing and say their methods could not separate that interference from actual oil oxidation. Do not turn an elevated result—or a flavored-versus-unflavored comparison—into a causal or product-safety conclusion. Historical comparison criteria are not automatically a finished-gummy specification.
For the proposed product, record two decisions before commissioning reports:
- Which method applies to the finished gummy? Ask the laboratory for the extraction and preparation approach, target analyte, flavor/color interference assessment, recovery or other suitability evidence, units and acceptance basis. If the method cannot answer the question, record the gap instead of calling the sample a pass or failure.
- Where and when is oxidation evaluated? Separate incoming oil or powder evidence from finished-gummy results, and identify release and stability time points in the actual package. An ingredient report does not automatically release the finished product.
These are procurement questions, not a statement that all gummy oxidation is unmeasurable. The cited surveys do not establish a universal industry failure rate or a Sucotond result. They show why sample, method and reporting scope must stay attached to a finding.
The final claim still needs a controlled manufacturing and quality file
FDA's dietary-supplement CGMP guide describes component identity and specifications, appropriate scientifically valid tests or examinations, finished-product specifications, packaging and label specifications, master/batch records and quality-control disposition. For an omega-3 gummy, those controls must connect to the selected material and the decision being made.
- Component: identify the received source material and define its fatty-acid/composition basis.
- Process: connect storage, handling, addition, mixing and commercial records to the identified batch.
- Method: define the analyte, preparation, matrix limitations, units, time point and acceptance criterion.
- Finished product: establish applicable fatty-acid, oxidation, contaminant and physical criteria and quality disposition.
- Package and label: reconcile the effective source/EPA/DHA wording, allergen statement, package and shelf-life support.
FDA Dietary Supplement CGMP Small Entity Compliance Guide
Keep sales, manufacturing, brand and evidence roles visible
Brooklyn project office
Sucotond USA coordinates non-confidential buyer inputs, commercial communication, evidence requests, project status and delivery planning. It does not select an oil source or approve a health/allergen claim for the brand.
Guangzhou production facility
The company identifies Sucotond (Guangzhou) Health Biotechnology Co., Ltd. as responsible for development, feasibility, production, in-process controls and batch records. Facility evidence and product evidence remain separate.
Brand / responsible firm
The brand defines the intended market, source, serving and claim basis, approves the formula/specification and obtains qualified ingredient-status, allergen, label, safety and substantiation review.
Ingredient supplier and laboratory
Supplier and laboratory records must match the exact material lot, sample, analyte, method and report. A COA or oxidation result does not automatically authorize public use or validate another batch.
Omega-3 gummy project questions
What information is needed before requesting an omega-3 gummy quote?
Define the intended source and supplier material, whether the target concerns ALA, EPA, DHA or a combination, the amount per serving and acceptable piece count, oil/powder/emulsion form, carrier and other ingredients, gummy and package direction, target market, evidence requirements and volume stage.
Is the total fish or algal oil amount the same as the EPA plus DHA amount?
No. Total source-oil or powder mass can include fatty acids and other material beyond EPA and DHA. Reconcile source material, assay basis, EPA amount, DHA amount, total omega-3 wording, serving and label units instead of using one number for all of them.
Do peroxide, p-anisidine and TOTOX answer the same oxidation question?
No. They describe different measurements or calculations. State the applicable specification source, method, sample preparation, units, flavor/matrix limitations, time point and acceptance decision. One result or calculated value is not a universal product-quality conclusion.
Can a published market study predict the quality of a Sucotond omega-3 gummy?
No. The cited surveys do not validate a finished gummy. One explicitly excluded gummies because of method limitations and also described flavor interference in oxidation measurements. Review the actual sample, matrix-suitable method, package and time point; the published results establish neither a Sucotond outcome nor an industry-wide failure rate.
What evidence can a brand request for a commercial omega-3 gummy project?
Define supplier and lot identity/composition records, source and applicable allergen review, approved formula and product specification, sample approval, master and batch records, agreed fatty-acid, oxidation and contaminant reports, package and label revision, stability evidence and quality disposition. Availability and disclosure rights depend on the project and document owners.
Request an omega-3 gummy feasibility map
Share the source/material status, intended EPA/DHA basis, serving, gummy system, package, market, volume stage, evidence expectations and timing. The review identifies open questions; it is not a formula, quote, method, result or production commitment.
Brooklyn, NY 11214